osteoporosis
Conditions
Brief summary
Incidence of fragility fractures during the study periode
Detailed description
Changes in BMD spine and hip from inclusion to study end (3 years), Changes in Bone Turnover Markers over the study period (CTX and P1NP),Proportion of patients meeting restart criteria ,Adverse events.
Interventions
DRUGTETRACYCLINE
DRUGALENDRONIC ACID
Sponsors
Odense University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of fragility fractures during the study periode | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in BMD spine and hip from inclusion to study end (3 years), Changes in Bone Turnover Markers over the study period (CTX and P1NP),Proportion of patients meeting restart criteria ,Adverse events. | — |
Countries
Denmark
Outcome results
None listed